Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-12 04:31:30 EDT

Explore

PostsPeople
LatestRanked
@killbaitphi.bsky.socialOct 5, 2026, 8:28 AM

Obesity Surpasses Other Malnutrition Forms in Philippines, Government Survey Reveals

🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅

#obesity #malnutrition #publichealth

👇👇👇

@midgardfinance.comOct 5, 2026, 7:00 AM

💉 #obesity #EASD2026

🇺🇸 $LLY #retatrutide took off 18.8% in type 2 diabetes, the most of six drugs. 🇩🇪 Boehringer's #survodutide, from 🇩🇰 $ZEAL: 9.8%, and 26% stopped for side effects. All randomised patients.

All of EASD in one post:
midgardfinance.com/blog/2026/10/04/easd-2026-roundup/

Horizontal bar chart titled "Weight loss with type 2 diabetes": weight lost by adults with obesity and type 2 diabetes on the top dose of six drugs, each beside its own trial's placebo, counting all randomised patients. Retatrutide 12 mg (TRIUMPH-2, 80 weeks): 18.8% against 5.1% on placebo. Tirzepatide 15 mg (SURMOUNT-2, 72 weeks): 14.7% against 3.2% on placebo. CagriSema 2.4/2.4 mg (REDEFINE 2, 68 weeks): 13.7% against 3.4% on placebo. Semaglutide 7.2 mg (STEP UP T2D, 72 weeks): 13.2% against 3.9% on placebo. Survodutide 6.0 mg (SYNCHRONIZE-2, 76 weeks): 9.8% against 3.9% on placebo. Orforglipron 36 mg (ATTAIN-2, 72 weeks): 9.6% against 2.5% on placebo. Retatrutide and survodutide, the two trials read out at the EASD congress, are drawn in purple and the other four in grey. These are separate trials of 68 to 80 weeks, not a head-to-head comparison.
@bigearthdata.aiOct 4, 2026, 9:23 PM

Cancer's "Obesity Paradox" May Have a Surprising Explanation
->SciTechDaily | More on "Diet microbiome and cancer immunotherapy" at BigEarthData.ai | #Obesity

@marfells.bsky.socialOct 3, 2026, 7:51 PM

Cinderace fanart ~
#fatfur #weight_gainer #cinderace #fat #obesity #weight_gain #weightgain

@heysannidhi.bsky.socialOct 3, 2026, 2:35 AM

Hair Loss Was Just the Start. Ozempic Users Are Also Reporting Nail Trouble

gizmodo.com/hair-loss-wa...

#WeightLoss #Ozempic #Health #Obesity #Diabetes

@jlbjournal.bsky.socialOct 2, 2026, 4:06 PM

Carlos Blanco-Camarillo and colleagues report that #Obesity induces elevated numbers of low-density #Neutrophils (LDN), but these perform #Phagocytosis and #NETosis less efficiently than LDN from individuals with normal weight

@pharmaphorum.bsky.socialOct 2, 2026, 12:13 PM

As the #EASD congress draws to a close, here's a round-up of some of the other #clinicaltrials in #diabetes and #obesity that drew our attention.

pharmaphorum.com/news/new-dia...

@thelancetendo.bsky.socialOct 2, 2026, 11:34 AM

Definition and diagnostic criteria of #clinical #obesity thelancet.com/journals/lan...
#BMI #obesity
#EASD2026

#MedSky #EndoSky

@spaldingnews.bsky.socialOct 2, 2026, 7:35 AM

A Spalding man reportedly vanished after dramatic weight loss injections, sparking local debate about obesity, health trends and modern treatments.

#Obesity #Mounjaro #Wegovy #Lincolnshire #Spalding

@midgardfinance.comOct 2, 2026, 7:00 AM

💉 #obesity

🇺🇸 #Retatrutide in TRIUMPH-1: 27% of patients lost more than a THIRD of their body weight at 80 weeks. The Phase 2 trial never reported that threshold.

At 30%+: 45% vs 26%. Longer trial, deeper loss.

midgardfinance.com/obesity/drugs/retatrutide/

$LLY

Grouped bar chart comparing retatrutide 12 mg against itself at two stages of its programme, showing the share of patients reaching each weight-loss threshold. Grey bars are the phase 2 trial at 48 weeks, which has no acronym, and blue bars the phase 3 trial TRIUMPH-1 at 80 weeks. At 25 per cent or more of body weight lost, Phase 2 reached 48 per cent of patients and Phase 3 62. At 30 per cent or more, Phase 2 reached 26 and Phase 3 45. At 35 per cent or more, Phase 3 reached 27 per cent and Phase 2 is absent because that trial never reported the threshold, which is labelled on the chart rather than drawn as a zero. Both readings are the efficacy estimand, the adherent population, so they are matched on that axis. They are not matched on duration: the Phase 3 trial ran 32 weeks longer, so part of every gap is more time on treatment rather than a difference between the programmes. The Phase 2 figures come from the published trial paper; the Phase 3 figures come from a sponsor press release, which is the primary source until the trial publishes but is a tier below a peer-reviewed table.
@bcmfromthelabs.bsky.socialOct 1, 2026, 8:08 PM

Scientists are exploring the possibility of targeting #brownFat to help treat cardiometabolic diseases, such as #obesity and type II #diabetes. M-H Chen et al show their findings in @cp-cellreports.bsky.social @bcmhouston.bsky.social blogs.bcm.edu/2026/10/01/a...

@sablesystems.bsky.socialOct 1, 2026, 5:02 PM

Less than a week to go until the #AdiposeBiology #Conference kicks off in Montreal, Canada (Oct 7–9)!

We'll be there as a proud partner of this important event. 😁

buff.ly/8qNkkHR

#Metabolism #Physiology #Respirometry #IndirectCalorimetry #Obesity #Thermogenesis

@pharmalot.bsky.socialOct 1, 2026, 2:10 PM

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Trump's plan to lower Medicare drug prices, a Lilly obesity drug, and more news.. statnews.com/pharmalot/20... #pharma #Trump #Medicare #obesity #weight #layoffs #FDA #animals #Lilly #Novo #AstraZeneca #Sanofi #Regeneron

@midgardfinance.comOct 1, 2026, 12:30 PM

💉 #obesity #EASD2026

🇩🇪 Boehringer's #survodutide, from 🇩🇰 Zealand, in obesity with type 2 diabetes. Phase 3, NEJM:

Weight, all randomised: -9.8% vs -3.9% placebo
On treatment: -13.1%
Stopped for side effects: 26% vs 9%. Four rivals: 6-11%

midgardfinance.com/obesity/drugs/survodutide/

$ZEAL

Scatter chart of five obesity drugs in their phase 3 trials in adults with obesity and type 2 diabetes, one point per drug at its top dose. Across: the share of patients who stopped the drug because of side effects. Down: average weight change counting all randomised patients. Semaglutide 7.2 mg (STEP UP T2D, 72 weeks): 6 per cent stopped, weight -13.2 per cent. Retatrutide 12 mg (TRIUMPH-2, 80 weeks): 7 per cent stopped, weight -18.8 per cent. CagriSema 2.4/2.4 mg (REDEFINE 2, 68 weeks): 8 per cent stopped, weight -13.7 per cent. Orforglipron 36 mg (ATTAIN-2, 72 weeks): 11 per cent stopped, weight -9.6 per cent. Survodutide 6 mg (SYNCHRONIZE-2, 76 weeks): 26 per cent stopped, weight -9.8 per cent. Four of the points sit between 6 and 11 per cent stopping; survodutide is alone on the right at 26 per cent, with about the same weight loss as the oral drug orforglipron. Survodutide's trial was published in the New England Journal of Medicine on 1 October 2026. These are separate trials with different participants and lengths, not a head-to-head comparison. Tirzepatide is not shown because its trial's published summary gives no comparable figure for stopping.
@pharmaj.bsky.socialOct 1, 2026, 11:15 AM

Clinical trial participants with #obesity and type 2 diabetes mellitus, who took #retatrutide at a dose of 12 mg, experienced an average of 20.8% weight loss over 80 weeks, study results show

#ukpharmacy #diabetes

buff.ly/mpbfIZE

@metabologiajnl.bsky.socialOct 1, 2026, 10:35 AM

Metabologia wants your research papers on the #metabolic aspects of #diabetes, #obesity #CVD and #renal and #hepatic disease #comorbidity #nutrition #exercise #psychosocial #healtheconomics #healthtechnology – submit now! metabologia.org #EASD2026

@thelancetendo.bsky.socialOct 1, 2026, 7:44 AM

Published in @thelancet.com

#Retatrutide in adults with #obesity and type 2 #diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial www.thelancet.com/journals/lan...
#T2D
#EASD2026

#MedSky #EndoSky

@boehringerglobal.bsky.socialOct 1, 2026, 7:36 AM

#NEWS: Phase III trial data for people living with #obesity, overweight & #T2D were presented today at @easdnews.bsky.social

These results will help us understand how survodutide can provide weight loss benefits whilst improving blood sugar levels.

👉 go.boehringer.com/SBqTr

#LifeForward #EASD2026

@foodnourish.bsky.socialOct 1, 2026, 7:25 AM

📣 New Podcast! "Why Childhood Obesity Rates Are Skyrocketing" on @Spreaker #activity #behavior #childhood #diet #disparities #epidemic #exercise #fitness #food #health #healthier #lifestyle #medicine #nutrition #obesity #parenting #pediatrics #prevalence #prevention #wellness

@easoobesity.bsky.socialOct 1, 2026, 7:07 AM

The EU intends to reduce premature cardiovascular deaths by 25% by 2035 through its #SafeHearts plan. Address #obesity to reduce diabetes prevalence and CV risk

commission.europa.eu/news-and-med...

Load more